WO2015076717A3 - Mscs in the treatment of cardiac disorders - Google Patents

Mscs in the treatment of cardiac disorders Download PDF

Info

Publication number
WO2015076717A3
WO2015076717A3 PCT/SE2014/000137 SE2014000137W WO2015076717A3 WO 2015076717 A3 WO2015076717 A3 WO 2015076717A3 SE 2014000137 W SE2014000137 W SE 2014000137W WO 2015076717 A3 WO2015076717 A3 WO 2015076717A3
Authority
WO
WIPO (PCT)
Prior art keywords
mscs
extracellular vesicles
methods
present
treatment
Prior art date
Application number
PCT/SE2014/000137
Other languages
French (fr)
Other versions
WO2015076717A2 (en
Inventor
Karl-Henrik GRINNEMO
Oscar Simonson
Original Assignee
Isletone Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isletone Ab filed Critical Isletone Ab
Publication of WO2015076717A2 publication Critical patent/WO2015076717A2/en
Publication of WO2015076717A3 publication Critical patent/WO2015076717A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to, inter alia, methods for culturing mesenchymal stem cells (MSCs) (without the use of non-human serum components), MSCs and extracellular vesicles obtained from such culturing methods, having advantageous polypeptide profiles which are key for immuno-modulatory efficacy. Further, the present invention pertains to pharmaceutical compositions comprising such MSCs and/or extracellular vesicles, and medical treatment and prophylactic methods and medical uses of MSCs and/or extracellular vesicles in a variety of diseases, notably myocarditis, pericarditis, cardiomyopathy and specifically dilated cardiomyopathy, and/or post-cardiotomy syndrome, and related diseases and ailments, such as organ failure.
PCT/SE2014/000137 2013-11-21 2014-11-20 Mscs in the treatment of cardiac disorders WO2015076717A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1300721 2013-11-21
SE1300721-6 2013-11-21

Publications (2)

Publication Number Publication Date
WO2015076717A2 WO2015076717A2 (en) 2015-05-28
WO2015076717A3 true WO2015076717A3 (en) 2015-07-16

Family

ID=52016126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2014/000137 WO2015076717A2 (en) 2013-11-21 2014-11-20 Mscs in the treatment of cardiac disorders

Country Status (1)

Country Link
WO (1) WO2015076717A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189842A1 (en) * 2016-04-27 2017-11-02 The Scripps Research Institute Extracellular vesicles from young stem cells or serum for age-related therapies
WO2018109525A1 (en) * 2016-12-14 2018-06-21 Università Degli Studi Di Padova New anti-angiogenic extracellurlar vesicles
EP3636271A4 (en) * 2017-06-09 2021-03-03 Osaka University Therapeutic agent for dilated cardiomyopathy
US20220062347A1 (en) * 2019-03-08 2022-03-03 Niigata University Induction method for macrophage, anti-inflammatory macrophage-inducing agent, and pharmaceutical composition
CN110777113B (en) * 2019-09-10 2021-09-24 中山大学 Mesenchymal stem cell processing method for schistosoma japonicum infection treatment
CN111471650B (en) * 2020-04-14 2021-07-27 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Exosome derived from human umbilical cord mesenchymal stem cells, identification method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDALOUSSI ET AL: "Extracellular vesicles: biology and emerging therapeutic opportunities", vol. 12, 1 May 2013 (2013-05-01), pages 347 - 357, XP055185310, Retrieved from the Internet <URL:http://www.nature.com/nrd/journal/v12/n5/pdf/nrd3978.pdf> [retrieved on 20150423] *
ANONYMOUS: "Markers & Methods to Verify Mesenchymal Stem Cell Identity, Potency, & Quality", 12 November 2013 (2013-11-12), XP002738912, Retrieved from the Internet <URL:http://www.rndsystems.com/mini_review_detail_objectname_mr_markers_methods_verify_mesenchymal_stem_cell_id_potency_quality.aspx> [retrieved on 20150423] *
K.H GRINNEMO ET AL: "Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 127, no. 5, 1 May 2004 (2004-05-01), pages 1293 - 1300, XP055185294, ISSN: 0022-5223, DOI: 10.1016/j.jtcvs.2003.07.037 *
LAI R C ET AL: "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury", STEM CELL RESEARCH, ELSEVIER, NL, vol. 4, no. 3, 1 May 2010 (2010-05-01), pages 214 - 222, XP027054731, ISSN: 1873-5061, [retrieved on 20100104] *
LEANDRO MAIA ET AL: "Immunophenotypic, immunocytochemistry, ultrastructural, and cytogenetic characterization of mesenchymal stem cells from equine bone marrow", MICROSCOPY RESEARCH AND TECHNIQUE, vol. 76, no. 6, 27 June 2013 (2013-06-27), pages 618 - 624, XP055185555, ISSN: 1059-910X, DOI: 10.1002/jemt.22208 *
MEHDI NAJAR ET AL: "Immune-Related Antigens, Surface Molecules and Regulatory Factors in Human-Derived Mesenchymal Stromal Cells: The Expression and Impact of Inflammatory Priming", STEM CELL REVIEWS AND REPORTS, HUMANA PRESS INC, NEW YORK, vol. 8, no. 4, 15 September 2012 (2012-09-15), pages 1188 - 1198, XP035144063, ISSN: 1558-6804, DOI: 10.1007/S12015-012-9408-1 *
ROBERT A. ROSE ET AL: "Bone Marrow-Derived Mesenchymal Stromal Cells Express Cardiac-Specific Markers, Retain the Stromal Phenotype, and Do Not Become Functional Cardiomyocytes In Vitro", STEM CELLS, vol. 26, no. 11, 1 November 2008 (2008-11-01), pages 2884 - 2892, XP055185308, ISSN: 1066-5099, DOI: 10.1634/stemcells.2008-0329 *

Also Published As

Publication number Publication date
WO2015076717A2 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
WO2015076717A3 (en) Mscs in the treatment of cardiac disorders
AU2018236800B2 (en) DNA-PK inhibitors
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA202091568A1 (en) GLUCOSYL CERAMIDE SYNTHASE INHIBITORS
WO2015028969A3 (en) Transduction buffer
EA201791717A1 (en) STABLE WATER COMPOSITIONS ADALIMUMAB
BR112014009087A2 (en) xylitol stabilized etanercept formulations
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
EA201101523A1 (en) METHODS OF TREATMENT OF METABOLIC DISORDERS, USING EPIMETABOLIC SWITCHES, MULTI-ASPECT INTRACELLULAR MOLECULES OR IMPACT FACTORS
BR112015006426A2 (en) nutritional compositions including beta-hydroxy-beta-methylbutyrate, protein and low electrolyte levels
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
BR112015000229A2 (en) stable aqueous formulations of etanercept
MY197024A (en) Amylin analogues
PH12017501674A1 (en) Amylin analogues
CL2011003003A1 (en) Reconstituted surfactant composition comprising a native surfactant protein c-analog polypeptide, a native surfactant protein-b-analog polypeptide, a monounsaturated phospholipid, and a saturated phospholipid, useful for the treatment of respiratory distress syndrome.
WO2015177175A3 (en) Novel specific-binding polypeptides and uses thereof
WO2014053418A3 (en) Method for obtaining mesenchymal stem cells and use thereof
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
BR112013001753A2 (en) a method for preparing a plasma erected alpha-inhibitor (aiip) composition, aqueous iaip solution, and a method for treating a disease or disorder associated with iaip dysfunction and associated with increased plasma serine protease activity.
MX2017002469A (en) Extracellular matrix compositions.
BR112017001550A2 (en) tissue graft
MX2013011833A (en) Infant formula for use in the prevention of cardiovascular diseases.
WO2015095735A3 (en) Vaccine compositions and uses thereof
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14809539

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14809539

Country of ref document: EP

Kind code of ref document: A2